Medicus Pharma receives FDA clearance to proceed with Phase 2b prostate cacner study

Medicus Pharma (NASDAQ:MDCX) received FDA 'study may proceed' clearance to start a Phase 2b dose‑optimization trial of Teverelix in 40 men with advanced prostate cancer and elevated cardiovascular risk; the open‑label study uses an initial loading regimen with maintenance dosing every six weeks across ~22 weeks, with the primary endpoint of sustained medical castration through Day 155. The company says the study will evaluate durability of hormone suppression and cardiovascular safety to support a potential registrational Phase 3 program focused on castration efficacy and cardiovascular outcomes; Medicus also retains a European CTA for the program and reported completed enrollment in a separate SkinJect doxorubicin Phase 2 for basal cell carcinoma with topline data expected in Q1 2026 and an end‑of‑Phase 2 FDA meeting planned in H1 2026.

Analysis

Contrarian angles: consensus may overstate commercial upside from a CV-focused label — realistic addressable population likely 15–30% of advanced PCa, and uptake constrained by formularies; therefore current positive sentiment could be underdone for MDCXW warrants but overdone for peers priced on disruption. Historical parallel: niche label claims (e.g., specialty hormone therapies) often produce modest share until clear real-world CV benefit and payer support; unintended consequences include partnership reluctance or aggressive dilution after positive Phase 2 signals, compressing near-term returns.

Key Decisions for Investors

• Establish a 1–2% portfolio long position in MDCX/MDCXW (equity or warrants) within 30 days to capture SkinJect Q1 2026 topline and Phase 2b initiation; set a hard stop at -50% loss and plan to take 50% profits at +100% and remainder at +200%.
• If listed, buy a 6–12 month MDCX call spread sized 1–3% (debit) rather than outright long equity to limit downside; target strike differential that caps cost to <0.5% of portfolio and plan roll/exit after Phase 2b Day 155 results (~June–Aug 2026).
• Implement a hedge: short 0.5–1.0% of portfolio in XBI or modest short in MYOV/PFE to neutralize sector beta if entering MDCX exposure; reduce hedge after confirmed non‑inferior CV safety signal at Phase 2b readout.
• Increase long exposure to 3–5% only upon two triggers: (1) SkinJect topline shows primary endpoint met Q1 2026 and (2) Phase 2b demonstrates sustained castration through Day 155 with no significant CV signals; if either fails, reduce position to zero immediately.
• Monitor near-term catalysts (SkinJect topline by end Q1 2026; FDA end-of-Phase‑2 meeting H1 2026; any partnership announcements). If implied volatility rises >30% vs 30‑day average pre-readout, switch to spread strategies to sell premium rather than buying naked options.